Connect with us

Markets

The World’s 50 Largest Pharmaceutical Companies

Published

on

The World's Largest Pharmaceutical Companies by Market Capitalization

The World’s 50 Largest Pharmaceutical Companies

Globally, big pharma revenues have grown by more than half a trillion dollars since 2012, driven by an aging global population.

American drugmakers make up the greatest market share worldwide by far, supported by high prices in a less regulated market. Yet with 190 drug patents expiring in the next decade, many companies face steep revenue losses at the hands of generic competitors.

This graphic, from Pranav Gavali, shows the largest pharmaceutical companies in the world.

Ranked: The Top 50 Pharmaceutical Giants

Together, the 50 biggest drugmakers make up a combined $4.7 trillion in market capitalization.

With a market cap of over $578 billion, American pharmaceutical company Eli Lilly is the world’s most valuable, known for diabetes medications and its newly-launched weight-loss drug. The average price of insulin in the U.S. is more than five times higher than other countries.

RankingNameSymbolMarket Cap
Oct 16 2023
Country
1Eli LillyLLY$578.3B🇺🇸 U.S.
2Novo NordiskNVO$452.8B🇩🇰 Denmark
3Johnson &
Johnson
JNJ$377.7B🇺🇸 U.S.
4MerckMRK$263.9B🇺🇸 U.S.
5AbbVieABBV$261.2B🇺🇸 U.S.
6RocheROG.SW$222.4B🇨🇭 Switzerland
7AstraZenecaAZN$212.2B🇬🇧 UK
8NovartisNVS$201.1B🇨🇭 Switzerland
9PfizerPFE$181.3B🇺🇸 U.S.
10AmgenAMGN$152.0B🇺🇸 U.S.
11SanofiSNY$138.5B🇫🇷 France
12Bristol-Myers
Squibb
BMY$118.0B🇺🇸 U.S.
13Gilead SciencesGILD$96.8B🇺🇸 U.S.
14Vertex
Pharmaceuticals
VRTX$95.8B🇺🇸 U.S.
15CVS HealthCVS$91.9B🇺🇸 U.S.
16Regeneron
Pharmaceuticals
REGN$91.1B🇺🇸 U.S.
17ZoetisZTS$80.3B🇺🇸 U.S.
18GlaxoSmithKlineGSK$76.6B🇬🇧 UK
19CSLCSL.AX$73.3B🇦🇺 Australia
20Merck KGaAMRK.DE$67.8B🇩🇪 Germany
21Daiichi Sankyō4568.T$51.7B🇯🇵 Japan
22Chugai
Pharmaceutical
4519.T$50.8B🇯🇵 Japan
23Takeda
Pharmaceutical
TAK$47.2B🇯🇵 Japan
24BayerBAYZF$45.1B🇩🇪 Germany
25SeagenSGEN$40.2B🇺🇸 U.S.
26Jiangsu Hengrui
Medicine
600276.SS$38.6B🇨🇳 China
27BiogenBIIB$38.0B🇺🇸 U.S.
28ModernaMRNA$37.4B🇺🇸 U.S.
29WuXi AppTec2359.HK$36.0B🇨🇳 China
30LonzaLONN.SW$34.2B🇨🇭 Switzerland
31Sun
Pharmaceutical
SUNPHARMA.NS$32.8B🇮🇳 India
32ArgenxARGX$29.9B🇳🇱 Netherlands
33West
Pharmaceutical
WST$28.4B🇺🇸 U.S.
34WuXi BiologicsWXXWY$26.7B🇨🇳 China
35Horizon
Therapeutics
HZNP$26.6B🇮🇪 Ireland
36BioNTechBNTX$24.8B🇩🇪 Germany
37Astellas Pharma4503.T$22.9B🇯🇵 Japan
38GenmabGMAB$21.1B🇩🇰 Denmark
39Alnylam
Pharmaceuticals
ALNY$21.0B🇺🇸 U.S.
40ICON plcICLR$20.3B🇮🇪 Ireland
41Walgreens Boots
Alliance
WBA$20.1B🇺🇸 U.S.
42BeiGeneBGNE$19.5B🇨🇳 China
43Otsuka
Holdings
4578.T$18.4B🇯🇵 Japan
44LabCorpLH$17.9B🇺🇸 U.S.
45Royalty PharmaRPRX$16.8B🇬🇧 UK
46BioMarin
Pharmaceutical
BMRN$16.2B🇺🇸 U.S.
47BaxterBAX$16.1B🇺🇸 U.S.
48UCBUCB.VI$16.0B🇧🇪 Belgium
49Eisai4523.T$15.9B🇯🇵 Japan
50Celltrion068270.KS$15.0B🇰🇷 South Korea

Ranking in second is Denmark’s Novo Nordisk, with a $453 billion market cap.

The 100-year old company began by making insulin, a newly discovered drug in the 1920s. Like Eli Lilly, it recently launched a weight-loss drug, Ozempic, originally used to treat diabetes. As drug sales soared, the company briefly became the most valuable in Europe.

According to BMO, the weight-loss drug market will be worth $100 billion by 2035.

As a major drug exporter to the U.S., Japan is home to the largest pharma companies in Asia. In fact, it is the third-largest pharmaceutical market in the world. A number of large U.S. pharma companies including Eli Lilly, Pfizer, and Bristol Myers Squibb have subsidiaries in the country.

Of the top 50 pharma companies, U.S. drugmakers make up 56% of global market capitalization, followed by Europe at 34%, and Asia with a 10% market share.

Facing a Cliff

With scores of patents set to expire by 2030, big pharma companies could see a $200 billion loss in revenues due to fierce competition from generics.

As a result, the 10 largest pharmaceutical companies globally are at risk of losing 46% of revenues. Adding to this, the U.S. government announced they may remove patent protection if certain drugs are too expensive in efforts to clamp down on high drug prices.

This may come as a benefit to consumers, especially in America. With some of the highest prescription costs in the world, they are as much as three times more expensive than other countries, averaging $1,432 per person in 2021.

The median price for newly-launched drugs in the U.S. in 2022 was over $200,000 per year—up from $2,115 in 2008.

green check mark icon

This article was published as a part of Visual Capitalist's Creator Program, which features data-driven visuals from some of our favorite Creators around the world.

Click for Comments

Markets

Visualizing The S&P 500’s Domestic and Foreign Revenues

In 2023, foreign sales made up 28% of the S&P 500’s revenue. Which sector was the most exposed to foreign sales?

Published

on

Visualizing The S&P 500’s Domestic and Foreign Revenues

This was originally posted on our Voronoi app. Download the app for free on iOS or Android and discover incredible data-driven charts from a variety of trusted sources.

As tariffs remain top of mind ahead of the upcoming U.S. election, some American industries may be more vulnerable to price fluctuations stemming from these trade policies.

Sectors reliant on foreign revenue are particularly vulnerable to the potential impact of stricter tariffs—a policy that Republican presidential candidate Donald Trump has consistently proposed.

This chart visualizes the share of S&P 500’s revenues that come from foreign and domestic sales, broken down by sector.

The data comes from a Goldman Sachs report via ZeroHedge and is updated as of June 2024.

How Much S&P 500 Revenues Come From Foreign Sources

Below, we show the breakdown of the S&P 500’s revenue between domestic and foreign sources in 2023.

SectorTotal Revenues ($bn)Foreign Revenues ($bn)Foreign Sales Exposure (%)Explicit Emerging Market (EM) Sales Exposure (%)
Information Technology$1,601$94259%17%
Materials$469$22147%12%
Energy$1,301$46936%3%
Industrials$1,666$53132%5%
Communication Services$1,236$36930%2%
Consumer Discretionary$2,011$54627%3%
Consumer Staples$2,211$57626%3%
Real Estate$154$3623%3%
Financials$1,973$43722%1%
Health Care$3,039$41914%1%
Utilities$420$102%2%
S&P 500$16,082$4,55628%4%

While foreign revenues made up just 28% of the S&P 500’s revenues in 2023, some sectors are more exposed to foreign sales than others.

The S&P 500’s information technology sector had the largest exposure to foreign sales, with 59% of its revenue coming from foreign sources–more than double the index’s average. The index’s information technology category includes big tech firms such as Apple, Nvidia, and Microsoft.

The IT sector of the S&P 500 is highly exposed to foreign sales primarily due to the global nature of technology businesses, which allows for easy distribution of digital products and services worldwide, and the pursuit of large international markets for growth opportunities.

This exposure is further amplified by the sector’s complex global supply chains and the inherent scalability of many tech offerings.

The materials sector is the second most exposed sector to foreign sales, and is made up of mining, chemicals, and forest product companies.

Looking at emerging market sales exposure specifically, the information technology sector is again the most exposed.

Learn More on the Voronoi App

To learn more about the S&P 500’s performance, check out this graphic that shows how the index fares after an interest rate cut.

Continue Reading
National Public Utilities Council 2024 Annual Utility Decarbonization Report - Download Free Report

Subscribe

Popular